X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
0.2217
-0.0147 (-6.22%)
At close: Apr 1, 2025, 4:00 PM
0.2210
-0.0007 (-0.32%)
After-hours: Apr 1, 2025, 4:36 PM EDT
X4 Pharmaceuticals Stock Forecast
XFOR's stock price has decreased by -84.01% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts with 12-month price forecasts for X4 Pharmaceuticals stock have an average target of 2.83, with a low estimate of 1.50 and a high estimate of 4.00. The average target predicts an increase of 1,176.50% from the current stock price of 0.22.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for X4 Pharmaceuticals stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 4 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $1.5 | Strong Buy | Reiterates | $1.5 | +576.59% | Mar 27, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $3 | Buy | Reiterates | $3 | +1,253.18% | Mar 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $1.5 | Strong Buy | Reiterates | $1.5 | +576.59% | Feb 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $1.5 | Strong Buy | Reiterates | $1.5 | +576.59% | Jan 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5 → $1.5 | Strong Buy | Maintains | $5 → $1.5 | +576.59% | Nov 14, 2024 |
Financial Forecast
Revenue This Year
12.72M
from 2.56M
Increased by 397.34%
Revenue Next Year
42.11M
from 12.72M
Increased by 231.16%
EPS This Year
-0.51
from -0.19
EPS Next Year
-0.40
from -0.51
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 21.0M | 63.0M | 332.8M | ||
| Avg | 12.7M | 42.1M | 128.6M | ||
| Low | 6.0M | 16.1M | 46.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 721.3% | 395.4% | 690.1% | ||
| Avg | 397.3% | 231.2% | 205.4% | ||
| Low | 135.1% | 26.7% | 9.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.33 | -0.20 | 0.27 | ||
| Avg | -0.51 | -0.40 | -0.11 | ||
| Low | -0.60 | -0.55 | -0.36 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.